Florencia Bonnin

Mx. Florencia Bonnin

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2022 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
Laura B. TalaricoLaura B. Talarico
Laura B. Talarico
ATAnalía Msc Toledano
Analía Msc Toledano
MCMaría Marta Contrini
María Marta Contrini
LTLidia E. Torrado
Lidia E. Torrado
MMMaría Paula Msc Martínez
María Paula Msc Martínez
ELEduardo Luis López
Eduardo Luis López
Background: Coronavirus disease 2019 (COVID-19) is usually mild and self-limited in children. However, a few Severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infections in children may progress to severe disease with respiratory distress or can result in a multisystem inflammatory syndrome (MIS-C) associated with COVID-19. The immune mechanisms for these differential clinical outcomes are largely unknown. Methods: A prospective cohort study was performed to analyze the laboratory parameters, antibody response, immune phenotypes and cytokine profiles of 51 children with different clinical presentations of COVID-19. Results: We found that the absolute lymphocyte counts gradually decreased with disease severity. Furthermore, SARS-CoV-2 IgG levels in the acute phase and convalescence were not significantly different in patients with different disease severity. A decrease in CD3+, CD4+ and CD8+ T cells was observed as disease severity increased. Both CD4+ and CD8+ T cells were activated in children with COVID-19, but no difference in the percentage of HLADR+-expressing cells was detected across the severity groups. In contrast, MIS-C patients exhibited augmented exhausted effector memory CD8+ T cells. Interestingly, the cytokine profile in sera of moderate/severe and MIS-C patients revealed an increase in anti-inflammatory IL-1RA and a suppression of tumor necrosis factor-α, RANTES, eotaxin and PDGF-BB. MIS-C patients also exhibited augmented IL-1β. Conclusions: We report distinct immune profiles dependent on severity in pediatric COVID-19 patients. Further investigation in a larger population will help unravel the immune mechanisms underlying pediatric COVID-19.

7 April 2023 in Transactions of the Royal Society of Tropical Medicine and Hygiene
Verified
Journal Article
Closed access
PDF file
ABAlana B Byrne
Alana B Byrne
Florencia BonninFlorencia Bonnin
Florencia Bonnin
ABAgostina Bruno
Agostina Bruno
MBMaría Manuela Bono
María Manuela Bono
MCMaría Marta Contrini
María Marta Contrini
Laura B. TalaricoLaura B. Talarico
Laura B. Talarico
Background: During the American epidemic, Zika virus (ZIKV) expanded rapidly through dengue virus (DENV)-endemic regions. We analyzed the presentation of ZIKV infection in patients from the City of Orán, Argentina, and compared some of its features with dengue presentation in the same region. Methods: A retrospective study was conducted at San Vicente de Paul Hospital during 2016–2018. Clinical and demographic characteristics, pre-existing immunity to DENV, viral load and type I interferon (IFN) responses were studied in 63 patients with ZIKV infection. Results: Clinical manifestations of ZIKV infection were generally mild compared with dengue, although rash (p<0.001) and itching (p<0.001) were significantly more prevalent in ZIKV patients. ZIKV patients aged <15 y manifested relatively mild disease compared with older ZIKV patients, showing a decreased prevalence of headache (p=0.008), retro-orbital pain (p=0.001) and arthralgia (p=0.001). Increased Zika incidence was observed in female patients (60.3%). Serum viral load was low to undetectable in ZIKV patients and was not associated with serum anti-DENV IgG titers. Interferon-α and IFN-β serum levels did not correlate with serum viral load in ZIKV patients. Conclusions: Clinical presentation of ZIKV and DENV infections is largely overlapping, presenting a challenge for diagnosis and risk assessment for uniquely at-risk populations.

12 July 2024 in Vaccine
Verified
Journal Article
Closed access
Florencia BonninFlorencia Bonnin
Florencia Bonnin
Laura B. TalaricoLaura B. Talarico
Laura B. Talarico
FFFausto M. Ferolla
Fausto M. Ferolla
PAPatricio L. Acosta
Patricio L. Acosta
EPEmily Phung
Emily Phung
ELEduardo L. López
Eduardo L. López

14 June 2024 in Microbes and Infection
Verified
Journal Article
Closed access
ABAlana B. Byrne
Alana B. Byrne
Florencia BonninFlorencia Bonnin
Florencia Bonnin
ELEduardo L. López
Eduardo L. López
FPFernando P. Polack
Fernando P. Polack
Laura B. TalaricoLaura B. Talarico
Laura B. Talarico

3 July 2026 in Viruses
Verified
Journal Article
Open access
PDF file
Florencia BonninFlorencia Bonnin
Florencia Bonnin
ABAgostina Bruno
Agostina Bruno
MBMaría Manuela Bono
María Manuela Bono
CLCarolina Anahí Lucero
Carolina Anahí Lucero
LNLudmila Niño
Ludmila Niño
Laura B. TalaricoLaura B. Talarico
Laura B. Talarico
Secondary dengue infections are often linked to more severe clinical outcomes, yet pre-existing antibodies may exert either protective or pathogenic effects. To evaluate the role of acute-phase dengue antibodies in pediatric dengue, we analyzed clinical and laboratory features, viremia, and antibody profiles in children infected with DENV-1. We conducted a retrospective study of patients under 18 years diagnosed with DENV-1 in Salta, Argentina. Viremia was quantified by real-time RT-PCR; acute-phase IgG antibodies (within 7 days from symptom onset) against DENV, DENV-1, and DENV-NS1 were measured by immunoassays, and neutralizing antibodies by plaque reduction neutralization tests. Among 151 patients (median age 12 years), 62% presented dengue with warning signs and one case progressed to severe dengue. Viremia was higher in probable primary infections than in probable secondary infections and did not correlate with disease severity. Probable secondary infections were characterized by acute-phase antibody profiles that did not associate with DENV viremia. Age-stratified analyses revealed that adolescents exhibited higher viremia levels than younger children in probable primary infections, while viremia levels were comparable across age groups in probable secondary infections. Furthermore, children younger than 10 years displayed acute-phase antibody levels similar to those of adolescents. In adolescents with probable secondary infections, anti-DENV and anti-DENV-1 IgG were inversely correlated with platelet counts, whereas neutralizing and anti-DENV-NS1 antibodies showed no association. Collectively, these findings indicate that probable secondary DENV infections in our pediatric cohort were characterized by acute-phase antibodies that were not associated with viremia control, and that in adolescents, anti-DENV and anti-DENV-1 IgG antibodies likely associated with platelet depletion. These results highlight important implications for vaccine design, underscoring the need for vaccines that elicit strong neutralizing responses while minimizing cross-reactivity and the risk of antibody dependent enhancement.

10 March 2026 in The Pediatric Infectious Disease Journal
Verified
Journal Article
Closed access
MQMarcelo O. Quipildor
Marcelo O. Quipildor
GSGabriela Rapetti Salik
Gabriela Rapetti Salik
Florencia BonninFlorencia Bonnin
Florencia Bonnin
MSMarcela Silveti
Marcela Silveti
JMJulio Moreno
Julio Moreno
Laura B. TalaricoLaura B. Talarico
Laura B. Talarico
Background: Vertical transmission of dengue virus (DENV) may produce a wide range of disease symptoms such as premature birth, low birth weight and miscarriages. Methods: We report and analyze 6 cases of vertical transmission of DENV type 2 in Salta Province, Argentina, during 2023. DENV infection in mothers and newborns was confirmed by the presence of NS1 antigen, viral nucleic acid and/or immunoglobulin M. Epidemiologic and clinical data were collected upon hospital admission, and laboratory parameters were determined during hospitalization. Results: Most pregnant women exhibited dengue symptoms during the peripartum period, with fever, headache and thrombocytopenia each affecting 66.7% of cases. Three mothers experienced gynecorrhagia. One mother presented with severe dengue and developed pleural effusion. The median time from maternal symptom onset to childbirth was 4 days (interquartile range [IQR] 3–4 days). All neonates were full term with appropriate weight for gestational age, and 4 were females. Three newborns were delivered vaginally, and 3 were delivered by cesarean section. Five cases were symptomatic and presented varied clinical manifestations, including fever (83.3%) and respiratory distress (66.7%). Three neonates had thrombocytopenia, with a median minimum platelet count of 69,500/mm 3 (IQR 38,000–81,500/mm 3 ). One newborn with severe dengue experienced plasma leakage. All newborns progressed favorably with symptomatic and supportive care after a median hospitalization of 9 days (IQR 8–12 days). Conclusion: DENV infection should be considered in the differential diagnosis for nonspecific acute febrile syndrome in pregnant women and neonates during dengue outbreaks to provide adequate clinical management of both mothers and infants.